Editas Medicine Inc (NASDAQ: EDIT) on Tuesday, soared 12.60% from the previous trading day, before settling in for the closing price of $2.54. Within the past 52 weeks, EDIT’s price has moved between $0.91 and $6.05.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -1.48%. The company achieved an average annual earnings per share of 34.40%. With a float of $82.95 million, this company’s outstanding shares have now reached $83.71 million.
Let’s determine the extent of company efficiency that accounts for 246 employees. In terms of profitability, gross margin is 85.89%, operating margin of -590.68%, and the pretax margin is -805.8%.
Editas Medicine Inc (EDIT) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Editas Medicine Inc is 0.91%, while institutional ownership is 54.28%. The most recent insider transaction that took place on Jun 03 ’25, was worth 769. In this transaction SVP, Chief Financial Officer of this company sold 446 shares at a rate of $1.72, taking the stock ownership to the 17,506 shares. Before that another transaction happened on Jun 03 ’25, when Company’s EVP, CHIEF SCIENTIFIC OFFICER sold 726 for $1.72, making the entire transaction worth $1,252. This insider now owns 69,519 shares in total.
Editas Medicine Inc (EDIT) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 34.40% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 27.74% during the next five years compared to -1.48% drop over the previous five years of trading.
Editas Medicine Inc (NASDAQ: EDIT) Trading Performance Indicators
Editas Medicine Inc (EDIT) is currently performing well based on its current performance indicators. A quick ratio of 3.08 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.68.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.04, a number that is poised to hit -0.39 in the next quarter and is forecasted to reach -1.08 in one year’s time.
Technical Analysis of Editas Medicine Inc (EDIT)
Looking closely at Editas Medicine Inc (NASDAQ: EDIT), its last 5-days average volume was 4.21 million, which is a jump from its year-to-date volume of 3.07 million. As of the previous 9 days, the stock’s Stochastic %D was 67.12%.
During the past 100 days, Editas Medicine Inc’s (EDIT) raw stochastic average was set at 81.59%, which indicates a significant increase from 80.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.27 in the past 14 days, which was higher than the 0.20 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.86, while its 200-day Moving Average is $1.99. However, in the short run, Editas Medicine Inc’s stock first resistance to watch stands at $3.11. Second resistance stands at $3.36. The third major resistance level sits at $3.64. If the price goes on to break the first support level at $2.57, it is likely to go to the next support level at $2.29. Should the price break the second support level, the third support level stands at $2.04.
Editas Medicine Inc (NASDAQ: EDIT) Key Stats
Market capitalization of the company is 239.42 million based on 83,713K outstanding shares. Right now, sales total 32,310 K and income totals -237,090 K. The company made 4,660 K in profit during its latest quarter, and -76,090 K in sales during its previous quarter.
